Appeal No. 95-2419
Application 07/850,770
Greene, “AIDS and the Immune System, Scientific American, pp. 99-105 (Sept. 1993).
Brown, AIDS Vaccine Trials Viewed With Caution,” The Washington Post Newspaper
(June 10, 1993).
Three documents of record which this merits panel discusses are:
Dirckx et al. (Dirckx), “Mutation of conserved N-glycosylation sites around the CD-4
binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity,”
Virus Research, Vol. 18, pp. 9-20 (1990).
Bolmstedt, et al., (Bolmstedt), “Effects of mutations in glycosylation sites and disulphide
bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus
envelope glycoproteins,” Journal of General Virology, Vol. 72, pp. 1269-77 (1991).
Lee et al. (Lee), “Non-random distribution of gp120 N-linked glycosylation sites important
for infectivity of human immunodeficiency virus type 1,” Proc. Natl. Acad. Sci., USA, Vol.
89, pp. 2213-17 (Mar. 1992).
The only rejection remaining in the appeal is that of claims 11 and 12 under
35 U.S.C. § 112, first paragraph (enablement). See pages 4-8 of the Supplemental
Examiner's Answer. We affirm. In addition, we raise other issues which the examiner
should consider upon return of the application.
DISCUSSION
By way of background, we refer to the paragraph bridging pages 2-3 of the
supporting specification where appellants explain the basis of the present invention:
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007